Stock Events

Stock Events

Cytokinetics 

$74.83
84
-$2.26-2.93% Today

Statistics

Day High
79.01
Day Low
72.15
52W High
77.09
52W Low
29.84
Volume
2,830,797,115
Avg. Volume
-
Mkt Cap
9.22B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-2.55
-2.07
-1.6
-1.12
Expected EPS
-1.6567
Actual EPS
N/A

Financials

-891.6%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
176.08MRevenue
-1.57BNet Income

Analyst Ratings

97.79Average Price Target
The highest estimate is 136.00.
From 14 ratings within the last 6 months. This is not an investment recommendation.
Buy
86%
Hold
14%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CYTK. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap178B
Amgen competes in the biopharmaceutical sector focusing on cardiovascular diseases, similar to Cytokinetics' focus.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb, having acquired MyoKardia, competes in developing treatments for cardiovascular diseases.
Novartis
NVS
Mkt Cap279.67B
Novartis offers a broad portfolio including treatments for heart failure, competing in the same therapeutic area as Cytokinetics.
Pfizer
PFE
Mkt Cap149.77B
Pfizer develops and markets drugs for a wide range of conditions, including cardiovascular diseases, making it a competitor.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline has a diverse pharmaceutical portfolio that includes treatments for heart disease, competing with Cytokinetics.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca has a strong focus on cardiovascular and metabolic diseases, directly competing with Cytokinetics' developments.
Merck
MRK
Mkt Cap277.02B
Merck operates in various therapeutic areas, including cardiovascular, competing with Cytokinetics' heart failure treatments.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical division Janssen, competes across various disease areas including cardiovascular.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie, while known for its work in immunology and oncology, also explores treatments in other areas, potentially competing with Cytokinetics.

About

There is no Profile data available for KK3A.MU.
Show more...
CEO
Mr. Robert I. Blum
Employees
498
Country
United States
ISIN
US23282W6057

Listings

MI
IT
1CYTK.MI
STU
DE
KK3A.STU
MU
DE
KK3A.MU
XNAS
US
CYTK

0 Comments

Share your thoughts

FAQ

What is Cytokinetics stock price today?▼
The current price of CYTK is $74.83 USD — it has decreased by -2.93% in the past 24 hours. Watch Cytokinetics stock price performance more closely on the chart.
What is Cytokinetics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cytokinetics stocks are traded under the ticker CYTK.
Is Cytokinetics stock price growing?▼
CYTK stock has risen by +25.6% compared to the previous week, the month change is a +15.23% rise, over the last year Cytokinetics has showed a +120.28% increase.
What is Cytokinetics market cap?▼
Today Cytokinetics has the market capitalization of 9.22B
When is the next Cytokinetics earnings date?▼
Cytokinetics is going to release the next earnings report on July 30, 2026.
What were Cytokinetics earnings last quarter?▼
CYTK earnings for the last quarter are -1.67 USD per share, whereas the estimation was -1.65 USD resulting in a -1.07% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cytokinetics revenue for the last year?▼
Cytokinetics revenue for the last year amounts to 176.08M USD.
What is Cytokinetics net income for the last year?▼
CYTK net income for the last year is -1.57B USD.
How many employees does Cytokinetics have?▼
As of May 06, 2026, the company has 498 employees.
In which sector is Cytokinetics located?▼
Cytokinetics operates in the Health & Wellness sector.
When did Cytokinetics complete a stock split?▼
The last stock split for Cytokinetics was on June 25, 2013 with a ratio of 1:6.
Where is Cytokinetics headquartered?▼
Cytokinetics is headquartered in South San Francisco, United States.